Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study)

INTRODUCTION: Hand-foot syndrome (HFS) is a common cutaneous side effect of capecitabine therapy. Apart from oral cyclooxygenase-2 (COX-2) inhibitor (celecoxib), there are no proven strategies for the prevention of HFS. However, celecoxib is associated with significant cardiotoxicity. To date, no st...

Descripción completa

Detalles Bibliográficos
Autores principales: Santhosh, Akhil, Kumar, Akash, Pramanik, Raja, Gogia, Ajay, Prasad, Chandra Prakash, Gupta, Ishaan, Gupta, Nishkarsh, Cheung, Winson Y., Pandey, Ravindra Mohan, Sharma, Atul, Batra, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117836/
https://www.ncbi.nlm.nih.gov/pubmed/35590388
http://dx.doi.org/10.1186/s13063-022-06353-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117836/
https://www.ncbi.nlm.nih.gov/pubmed/35590388
http://dx.doi.org/10.1186/s13063-022-06353-2

Ejemplares similares